Summary

U.S. Renal Denervation Catheter Market Summary

The U.S. renal denervation catheter market size was estimated at USD 23.20 million in 2025 and is projected to reach USD 182.70 million by 2033, growing at a CAGR of 29.43% from 2025 to 2033. The growth is driven by the rising prevalence of hypertension and growing awareness about the limitations of pharmacological treatments, increasing clinical evidence supporting the safety and efficacy of renal denervation, and favorable regulatory advancements, such as the recent FDA approval, are further accelerating market adoption.

According to data released by the National Center for Health Statistics and the National Health and Nutrition Examination Survey in October 2024, the prevalence of hypertension among U.S. adults was 23.4% for those aged 18-39, rising to 52.5% for individuals aged 40-59, and reaching 71.6% for those aged 60 and older during the period from August 2021 to August 2023.

The high prevalence of hypertension is one of the primary drivers for the U.S. renal denervation catheter industry. In addition, a growing subset of patients suffers from treatment-resistant hypertension, which does not respond adequately to multiple antihypertensive medications. This widespread burden of disease creates a strong clinical need for alternative therapeutic interventions, such as renal denervation, which offers a non-pharmacological approach to long-term blood pressure control. As awareness and diagnosis rates improve, the eligible patient pool for RDN procedures is expected to expand, further propelling market demand.

U.S. Renal Denervation Catheter Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2025 to 2033. For this study, Grand View Research has segmented the U.S. renal denervation catheter market report based on product and end use:

• Product Outlook (Revenue, USD Million, 2025 - 2033)
• Radiofrequency (RF) Ablation Catheters
• Ultrasound Ablation Catheters
• End Use Outlook (Revenue, USD Million, 2025 - 2033)
• Hospitals
• Other

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.5.5. Information Analysis
1.5.6. Data Analysis Models
1.6. Market Formulation & Data Visualization
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Renal Denervation Catheter Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising prevalence of hypertension as a leading cause of cardiovascular disease
3.2.1.2. Growing regulatory approvals
3.2.1.3. Increasing awareness about hypertension management market restraint analysis
3.2.2. Market Restraint Analysis
3.2.2.1. Potential adverse events and complications associated with renal denervation catheters
3.2.2.2. Shortage of cardiologists
3.2.3. Market Opportunities Analysis
3.2.3.1. Growing clinical trials for renal denervation catheters
3.2.3.2. Improving reimbursement for renal denervation catheters
3.2.3.3. Strategic investments for renal denervation product portfolio expansion
3.2.3.4. Advancing multielectrode RDN catheters with dual access capabilities
3.2.4. Market Challenges Analysis
3.2.4.1. Stringent regulations
3.3. U.S. Renal Denervation Catheter Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political & Legal Landscape
3.3.2.2. Economic and Social Landscape
3.3.2.3. Technological landscape
Chapter 4. U.S. Renal Denervation Catheter Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Renal Denervation Catheter Market Product Movement Analysis
4.3. U.S. Renal Denervation Catheter Market Size & Trend Analysis, by Product, 2025 to 2033 (USD Million)
4.4. Radiofrequency (RF) Ablation Catheters
4.4.1. Radiofrequency (RF) Ablation Catheters Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
4.5. Ultrasound Ablation Catheters
4.5.1. Ultrasound Ablation Catheters U.S. Renal Denervation Catheter Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
Chapter 5. U.S. Renal Denervation Catheter Market: End Use Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Renal Denervation Catheter Market End Use Movement Analysis
5.3. U.S. Renal Denervation Catheter Market Size & Trend Analysis, by End Use, 2025 to 2033 (USD Million)
5.4. Hospitals
5.4.1. Hospitals U.S. Renal Denervation Catheter Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
5.5. Other
5.5.1. Other U.S. Renal Denervation Catheter Market Revenue Estimates and Forecasts, 2025 - 2033 (USD Million)
Chapter 6. Competitive Landscape
6.1. Market Participant Categorization
6.2. Key Company Profiles
6.2.1. Recor Medical, Inc. (Otsuka Medical Devices Co., Ltd.)
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Product Benchmarking
6.2.1.4. Strategic Initiatives
6.2.2. Medtronic
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Product Benchmarking
6.2.2.4. Strategic Initiatives
6.2.3. Boston Scientific Corporation
6.2.3.1. Company Overview
6.2.3.2. Financial Performance
6.2.3.3. Product Benchmarking
6.2.3.4. Strategic Initiatives
6.2.4. MicroPort Scientific Corporation
6.2.4.1. Company Overview
6.2.4.2. Financial Performance
6.2.4.3. Product Benchmarking
6.2.4.4. Strategic Initiatives
6.2.5. EnligHTN, St. Jude Medical (Abbott Laboratories)
6.2.5.1. Company Overview
6.2.5.2. Financial Performance
6.2.5.3. Product Benchmarking
6.2.5.4. Strategic Initiatives
6.2.6. Ablative Solutions, Inc.
6.2.6.1. Company Overview
6.2.6.2. Financial Performance
6.2.6.3. Product Benchmarking
6.2.6.4. Strategic Initiatives